169 related articles for article (PubMed ID: 36418474)
1. Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP.
McFall T; Trogdon M; Guizar AC; Langenheim JF; Sisk-Hackworth L; Stites EC
NPJ Precis Oncol; 2022 Nov; 6(1):86. PubMed ID: 36418474
[TBL] [Abstract][Full Text] [Related]
2. More to the RAS Story: KRAS
Lietman CD; Johnson ML; McCormick F; Lindsay CR
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35561303
[TBL] [Abstract][Full Text] [Related]
3. Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRAS
Ryan MB; Fece de la Cruz F; Phat S; Myers DT; Wong E; Shahzade HA; Hong CB; Corcoran RB
Clin Cancer Res; 2020 Apr; 26(7):1633-1643. PubMed ID: 31776128
[TBL] [Abstract][Full Text] [Related]
4. Targeting Kras
Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
[TBL] [Abstract][Full Text] [Related]
5. Targeting PI3Kα overcomes resistance to KRas
Qi WL; Li HY; Wang Y; Xu L; Deng JT; Zhang X; Wang YX; Meng LH
Acta Pharmacol Sin; 2023 May; 44(5):1083-1094. PubMed ID: 36411339
[TBL] [Abstract][Full Text] [Related]
6. Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors.
Matsubara H; Miyoshi H; Kakizaki F; Morimoto T; Kawada K; Yamamoto T; Obama K; Sakai Y; Taketo MM
Mol Cancer Ther; 2023 Apr; 22(4):529-538. PubMed ID: 36780229
[TBL] [Abstract][Full Text] [Related]
7. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
8. KRAS
Ryan MB; Coker O; Sorokin A; Fella K; Barnes H; Wong E; Kanikarla P; Gao F; Zhang Y; Zhou L; Kopetz S; Corcoran RB
Cell Rep; 2022 Jun; 39(12):110993. PubMed ID: 35732135
[TBL] [Abstract][Full Text] [Related]
9. Characterizing the
Li M; Keshavarz-Rahaghi F; Ladua G; Swanson L; Speers C; Renouf DJ; Lim HJ; Davies JM; Gill S; Stuart HC; Yip S; Loree JM
Ther Adv Med Oncol; 2022; 14():17588359221097940. PubMed ID: 35694189
[TBL] [Abstract][Full Text] [Related]
10. EGFR Blockade Reverts Resistance to KRAS
Amodio V; Yaeger R; Arcella P; Cancelliere C; Lamba S; Lorenzato A; Arena S; Montone M; Mussolin B; Bian Y; Whaley A; Pinnelli M; Murciano-Goroff YR; Vakiani E; Valeri N; Liao WL; Bhalkikar A; Thyparambil S; Zhao HY; de Stanchina E; Marsoni S; Siena S; Bertotti A; Trusolino L; Li BT; Rosen N; Di Nicolantonio F; Bardelli A; Misale S
Cancer Discov; 2020 Aug; 10(8):1129-1139. PubMed ID: 32430388
[TBL] [Abstract][Full Text] [Related]
11. Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors.
Rathod LS; Dabhade PS; Mokale SN
Drug Discov Today; 2023 May; 28(5):103557. PubMed ID: 36934967
[TBL] [Abstract][Full Text] [Related]
12. Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS
Li S; Liu S; Deng J; Akbay EA; Hai J; Ambrogio C; Zhang L; Zhou F; Jenkins RW; Adeegbe DO; Gao P; Wang X; Paweletz CP; Herter-Sprie GS; Chen T; Gutiérrez-Quiceno L; Zhang Y; Merlino AA; Quinn MM; Zeng Y; Yu X; Liu Y; Fan L; Aguirre AJ; Barbie DA; Yi X; Wong KK
Clin Cancer Res; 2018 Oct; 24(19):4854-4864. PubMed ID: 29945997
[No Abstract] [Full Text] [Related]
13. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors.
Stites EC; Shaw AS
CPT Pharmacometrics Syst Pharmacol; 2018 May; 7(5):342-351. PubMed ID: 29484842
[TBL] [Abstract][Full Text] [Related]
14. Drugging the Undruggable: Advances on RAS Targeting in Cancer.
Molina-Arcas M; Samani A; Downward J
Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34200676
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS
Hoshiyama H
Nihon Yakurigaku Zasshi; 2023; 158(5):391-398. PubMed ID: 37673617
[TBL] [Abstract][Full Text] [Related]
16. Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers.
Khan HY; Nagasaka M; Li Y; Aboukameel A; Uddin MH; Sexton R; Bannoura S; Mzannar Y; Al-Hallak MN; Kim S; Beydoun R; Landesman Y; Mamdani H; Uprety D; Philip PA; Mohammad RM; Shields AF; Azmi AS
Cancer Res Commun; 2022 May; 2(5):342-352. PubMed ID: 35573474
[TBL] [Abstract][Full Text] [Related]
17. Loss of wild type KRAS in KRAS
Liu Y; Gao GF; Minna JD; Williams NS; Westover KD
Lung Cancer; 2021 Mar; 153():73-80. PubMed ID: 33465697
[TBL] [Abstract][Full Text] [Related]
18. KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor.
Serna-Blasco R; Sánchez-Herrero E; Sanz-Moreno S; Rodriguez-Festa A; García-Veros E; Casarrubios M; Sierra-Rodero B; Laza-Briviesca R; Cruz-Bermúdez A; Mielgo-Rubio X; Sánchez-Hernández A; Uribelarrea EA; Calvo V; Romero A; Provencio M
ESMO Open; 2021 Oct; 6(5):100279. PubMed ID: 34607284
[TBL] [Abstract][Full Text] [Related]
19. KRAS
Lou K; Steri V; Ge AY; Hwang YC; Yogodzinski CH; Shkedi AR; Choi ALM; Mitchell DC; Swaney DL; Hann B; Gordan JD; Shokat KM; Gilbert LA
Sci Signal; 2019 May; 12(583):. PubMed ID: 31138768
[TBL] [Abstract][Full Text] [Related]
20. [Gene mutation profiles and clinicopathological features of patients with non-small cell lung cancer harboring KRAS G12C mutation: a single-center retrospective study].
Guo LY; Xiang C; Zhao RY; Chen SN; Ma SJ; Han YC
Zhonghua Bing Li Xue Za Zhi; 2023 Feb; 52(2):117-123. PubMed ID: 36748130
[No Abstract] [Full Text] [Related]
[Next] [New Search]
